Anxiety Disorders And Depression Treatment Market Size, Share & Trends Analysis Report By Drug (Antidepressants, Anxiolytics, Anticonvulsants, & Others), By Indication, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030

 Market Size & Trends

“2030 anxiety disorders and depression treatment market value to reach USD 15.88 billion”

The global anxiety disorders and depression treatment market size was estimated at USD 12.43 billion in 2023 and is projected to grow at a CAGR of 3.6% from 2024 to 2030. The rise in anxiety and depression in young adults is a complex issue with various causes, including excess social media usage, academic pressure, and financial stress which in turn is fueling the market growth. Young adults, typically defined as individuals between 18⁠-⁠30 years old, are among the age groups most vulnerable to anxiety & depression risks.

The occurrence of both of these conditions worldwide has risen significantly since the mid-twentieth, harming the educational and professional achievements of young individuals further resulting in excess substance abuse and suicides in extreme cases.

The rise of this market is also due to the increase in research and development investments done by governments and healthcare institutes further resulting in approvals of newer drugs useful for the treatment of these disorders. Furthermore, the market is also growing due to the collaboration of pharmaceutical companies, NGOs, mental health organizations, and government initiatives to raise awareness among populations which has educated patients about their mental health and also to seek medical help at the right time.

Drugs Insights

“The atypical antipsychotics segment to witness a growth rate of 4.9%”

The antidepressants segment dominated the market and accounted for the highest revenue share of 32.6% in 2023.  The increase in diseases like major depressive disorder, obsessive-compulsive disorder, generalized anxiety disorder, and panic disorder is a key factor contributing to the growth of this market. Awareness of mental health and depression, which has increased due to efforts taken by governments and various NGOs, has also led to increasing in the use of antidepressant drugs prescribed by doctors.

The atypical antipsychotics segment had a market share of 19.64% in 2023 as these drugs have a lesser side effect profile in comparison to typical psychotic drugs in terms of extrapyramidal symptoms. The segment growth is also attributed to the rise in conditions such as anxiety, depression, and bipolar disorders in the population. With growing mental health awareness, the population seeking treatment prefers these drugs as a first-line treatment due to their safety and efficacy.

Indication Insights

“The depression segment to witness a growth rate of 3.2%”

The anxiety segment dominated the market and accounted for a share of 55.2% in 2023. This can be attributed to the increased presence of phobias, social anxiety disorders, and other similar conditions in both established and growing economies. With the rise of population, there is an increase in competition in every field, which has led to unrealistic goal setting by the population. This high competition has led to a decrease in success rates and unrealistic goals lead to anxiety and depression when they are unfulfilled. Growing awareness about anxiety and its cure is acting as a growth factor for the market.

The depression segment accounted for a market share of 44.8% in the year 2023. With increased awareness of mental health, there is a rise in diagnoses, which has increased the number of populations willing to seek medical help. Furthermore, societal pressure, work-life balance challenges, and social media influence have also contributed to the increasing depression cases further contributing to the growth of this market. 

Distribution Channel Insights

“The online pharmacies segment to witness a growth rate of 8.6%”

The retail pharmacies segment dominated the market with a share of 55.6% in 2023. This is due to the preference of patients to buy medicines from nearby pharmacies, as they are easily accessible and trustworthy. Furthermore, the segment is growing as retail pharmacies provide branded along with generic medicines and other medical products all under one roof. Retail pharmacies provide immediate aid in emergencies that can be offered without prescriptions. Retail pharmacies can gather a large number of loyal customers due to their quick and seamless service therefore helping in the segment growth.

The online pharmacies segment is set to grow substantially with an increase in various e-commerce websites and apps providing medicines and other pharmacy products. Moreover, the segment is growing in this market, as customers are able to browse through online catalogues to buy the products and order them directly to their address without actually visiting the store. The subscription model in online pharmacies is also a growth factor as customers are able to order medicines on a monthly or weekly subscription solving the problem of medicine shortage.

Regional Insights

“Canada to witness market growth of CAGR 3.5%”

North America dominated the market with a share of 37.8% in the year 2023. It is attributable to the rise in the rate of mental and anxiety disorders within the population. North America is the market leader due to the presence of key market players and strong distribution channels in this segment. Furthermore, the availability of better medical facilities and medicines treating disorders related to mental health also assists in the market growth for this region.

U.S. Anxiety Disorders And Depression Treatment Market Trends

The anxiety disorders and depression treatment market in the U.S. dominated the market with a share of 89.3% in 2023 due to an increase in the symptoms related to mental disorders in the U.S. population such as depression, fear, a feeling of failure, and helplessness. An increase in awareness of mental health due to initiatives taken by the government and NGOs has furthermore assisted the market to grow significantly in this country.

Europe Anxiety Disorders And Depression Treatment Market Trends

Europe anxiety disorders and depression treatment market was identified as a lucrative region in this industry with a market share of 29.3% in 2023 due to significant investments in research and development for the creation of antidepressant medications. Increased sales of products for anxiety and depression disorders due to increasing in mental health awareness have furthermore assisted in the market growth for this region.

Asia Pacific Anxiety Disorders And Depression Treatment Market Trends

The anxiety disorders and depression treatment market in Asia Pacific had a market share of 23.6% attributed to the rise in mental disorders. Furthermore, the rise in the economic growth of countries such as China, Japan, and India has contributed to the growth of this market in this region.

 Key Anxiety Disorders And Depression Treatment Company Insights

Some major companies in the market are Pfizer Inc., H. Lundbeck A/S, Glaxo SmithKline Pharmaceuticals Ltd., and Merck & Co., Inc. Companies in this market focus on offering mental health treatments with drugs and other therapies. The companies also aim to grow by increasing new drug approvals and improving their distribution networks.  

• Pfizer, Inc. is a pharmaceutical and biomedical company, specializing in the research, production, and promotion of medications and vaccines for both people and animals. Pfizer collaborates with healthcare providers, governments, and local communities to support and expand access to healthcare around the world.

• H. Lundbeck A/S is a pharmaceutical company that is involved in researching, developing, producing, promoting, and selling pharmaceutical products worldwide. The company's focuses on products designed for brain disorders such as depression, schizophrenia, Alzheimer's, Parkinson's, and migraines.

Recent Developments

• In September 2023, Lundbeck presented clinical findings at the International Headache Congress (IHC) 2023 in Seoul, Korea, confirming the effectiveness and tolerability of Lu AG09222 in preventing migraines, a common symptom in many patients suffering from anxiety disorders. The presentations also featured extra information from a study proving that Lu AG09222 is able to prevent PACAP38-induced vasodilation and headaches.

Anxiety Disorders And Depression Treatment Market Report Scope

Global Anxiety Disorders And Depression Treatment Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, Grand View Research has segmented the global anxiety disorders and depression treatment market report based on drugs, indication, distribution channel, and region.  

• Drugs Outlook (Revenue, USD Million, 2018 - 2030)

  • Antidepressants

  • Anxiolytics

  • Anticonvulsants

  • Noradrenergic Agents

  • Atypical Antipsychotics

• Indication Outlook (Revenue, USD Million, 2018 - 2030)

  • Depression

  • Anxiety

• Distribution Channel Outlook (Revenue, USD Million, 2018 - 2030)

  • Hospital Pharmacies

  • Retail Pharmacies

  • Online Pharmacies

• Regional Outlook (Revenue, USD million, 2018 - 2030)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • Germany

    • UK

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • China

    • Japan

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East and Africa (MEA)

    • Saudi Arabia

    • UAE

    • South Africa

    • Kuwait